A SAFE is not a debt instrument — it has no maturity date, no interest rate, and no obligation to repay principal. A convertible note is a loan that accrues interest and matures on a specified date, requiring repayment or conversion. This difference is fundamental: SAFEs eliminate the risk of an accelerated maturity triggering insolvency, while convertible notes create real debt obligations that can complicate future financing if the company misses its fundraising timeline.
The most fundamental difference between a convertible note and a SAFE is that a note is debt and a SAFE is not. A convertible note accrues interest, typically at 5-8% annually, which increases the effective conversion amount over time. A convertible note has a maturity date, usually 18-24 months, at which point the company technically owes the principal plus accrued interest as a debt obligation if conversion has not occurred. A SAFE has neither interest nor maturity. In Gurpreet Bal's practice at Foley and Lardner, approximately 80% of seed-stage financings in Silicon Valley now use SAFEs rather than convertible notes, though notes remain common in certain investor communities and geographies.
Convertible notes can make more sense in jurisdictions where SAFEs are not well understood or enforceable, in later-stage bridge financings where investors require the security of debt treatment, or when the investor's fund documents require that instruments be classified as debt rather than equity. In some international contexts, notes also offer clearer treatment under local securities law.
Despite the dominance of SAFEs in Silicon Valley, convertible notes remain the better instrument in certain situations. Notes provide stronger creditor protection for investors in companies with significant existing liabilities or uncertain business models. The maturity date creates a natural forcing function for the company to either raise a priced round or renegotiate terms. In Gurpreet Bal's experience, notes are more common in bridge financings between priced rounds, in fundraises involving institutional investors who require debt instruments for portfolio accounting purposes, and in situations where the investor wants the additional protections that come with creditor status.
SAFEs convert automatically upon a qualified financing with no further action required by the holder. Convertible notes typically require the holder to elect conversion or may convert automatically depending on the note terms. Notes also accrue interest, which converts alongside principal — meaning the note holder receives more shares than a SAFE holder who invested the same principal amount at the same cap.
Both instruments convert into preferred stock at a future priced financing, but the triggers and mechanics differ. A SAFE typically converts only upon an equity financing above a specified threshold, a change of control event, or an IPO. A convertible note converts upon the same triggers but also includes the maturity date as a backstop. Discount rates, which give the seed investor a lower price per share than the Series A investors, are common in both instruments. Gurpreet S. Bal advises founders to understand the precise conversion triggers and mechanics before signing either instrument.
Both instruments ultimately dilute founders at Series A, but convertible notes dilute slightly more due to accrued interest converting into additional shares. The more important cap table consideration is whether instruments are pre-money or post-money SAFEs, and how many outstanding instruments convert simultaneously — stacked SAFEs and notes from a rolling seed round can create significant unexpected dilution when they all convert at the same time.
The practical cap table impact of notes versus SAFEs at Series A can differ because of interest accrual. A $1 million convertible note at 6% interest held for 18 months converts as approximately $1.09 million of equity, while a $1 million SAFE converts at exactly $1 million. Over multiple notes with multiple interest rates and different closing dates, the accrued interest can represent meaningful additional dilution. Gurpreet Bal models these effects for founders before they choose between instruments.
Gurpreet's view is that SAFEs are genuinely good for companies, and good enough for pre-seed investors who are already investing on a hope and a prayer. At that stage, the investment thesis is binary — either the company fails entirely, or it returns 30x and the marginal economics of the instrument barely matter either way. Spending significant time negotiating note mechanics at pre-seed is mostly wasted energy. The calculus shifts when the investing thesis has a narrower range of expected outcomes — a bridge round, a later-stage seed, a situation where the investor has a more defined return target. That is when the protections that come with debt structure — interest accrual, maturity forcing function, creditor status — start to matter, and when convertible notes deserve serious consideration over SAFEs.
Gurpreet S. Bal is a Partner at Foley and Lardner LLP in Silicon Valley, where he advises startups, founders, and investors on SAFE financings, venture capital rounds, mergers and acquisitions, acquihires, and IPOs. He has represented clients in hundreds of transactions with aggregate deal value exceeding $60 billion across AI, semiconductors, fintech, and emerging technology.